This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Jill and Carlo discuss the pending approval for Pfizer's vaccine for kids, the state of anti-Semitism three years after Tree of Life, potential criminal charges in the 'Rust' prop gun shooting and more.
Amalgamated Bank is the first U.S. bank to publish science-based targets to reach net-zero greenhouse gas emissions by 2045. The bank says it will reach this goal through how it engages with customers and how it finances projects. Amalgamated Bank Chief Sustainability Officer Ivan Frishberg joined Cheddar Climate to provide more details about the bank's ambitious climate goals.
COP26 been dealt a blow as Chinese President Xi Jinping and Russian President Vladimir Putin, whose countries are responsible for a third of the world's annual greenhouse gas emissions, will not be in attendance. Bertrand Piccard, Chairman and Founder of the Solar Impulse Foundation, joins Cheddar Climate, where he discusses what he expects to see when the summit commences in Glasgow.
John Nosta, WHO Technology Expert, joins Cheddar News to discuss evolving technology in the healthcare industry and the role 5G is playing in advancing healthcare delivery.
According to the latest report from the UN, several countries around the world are "nowhere near" towards their goal of limiting gas emissions. This report comes ahead of the COP26 which is slated to take place in the month of November in Scotland. Senior Advisor at CDP Paula Diperna, joined Cheddar to discuss what the report highlights and what this tells us about the future plans of the Paris Climate Agreement.
Powerful weather systems over California have caused record amounts of rainfall in the state, including over wildfire-scorched lands since triggering massive landslides.
The FDA meets today on whether or not vaccines for children ages 5-11 can potentially become available to the public. Cheddar News was joined by Dr. Richard Besser, President and CEO of the Robert Wood Johnson Foundation and former Acting Director of the CDC to discuss what could come next for these vaccines.
Dan DePodwin, Director of Forecasting Operations at AccuWeather, joined Wake Up With Cheddar to talk about the extreme weather across the country, including damaging rains in the drought-stricken western U.S. and an incoming Nor'easter that's likely to cause flooding and power outages along the Atlantic coast.
Jill and Carlo cover the news out of Facebook's latest earnings, Tesla's monumental day, Dave Chappelle addresses controversy and the tragedy of the climate emergency.
The UN's World Meteorological Organization reported that carbon dioxide in the atmosphere hit record levels in 2020, despite coronavirus-related lockdowns. With the COP26 international meeting on climate change less than a week away, Risk and behavioral scientist Dr. Sweta Chakraborty joined Cheddar to break down the "code red for humanity" the report represents and what actual commitments must be made to prevent significant global temperature increases.
